Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IMM-529

Vaccine (Peptide vaccine) · Immune activation · developed by Immuron

Phase 1/2 Most advanced trial (none active)
IMRN Developer
1 Registered trials

What is IMM-529?

IMM-529 is a vaccine candidate designed to prevent Clostridium difficile infection and recurrence by activating immune responses against C. difficile toxins.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Immuron Ltd. (IMRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03065374 Phase 1/2 Clostridium Difficile Infection Terminated IMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridium Difficile InfectionClostridium Difficile Infection Recurrence

More from Immuron

IMM-124E Phase 2 Travelan Phase 2

Follow IMRN, the company behind IMM-529

See IMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.